<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6973187/results/search/drug/results.xml">
  <result pre="(VL) increased to 132 × 106 copies/ml, treatment with 5 mg/kg weekly intravenous" exact="cidofovir" post="with concomitant hydration only obtained a moderate decrease in"/>
  <result pre="that could have caused cholestasis, BCV treatment was stopped and" exact="Cidofovir" post="was restarted. However, as HAdV reactivated, BCV was restarted"/>
  <result pre="in immunocompromised patients is ineffective without immune reconstitution [6, 7]." exact="Cidofovir" post="requires regular intravenous dosing but only achieves low in"/>
  <result pre="This might obtain viral control but hardly ever viral clearance." exact="Cidofovir" post="is most effective as prophylaxis with increasing titres on"/>
  <result pre="Cidofovir, can achieve over 100-fold higher intracellular levels compared with" exact="Cidofovir" post="(see Figure 2(b)). The low plasma levels promote less"/>
  <result pre="Figure 1 The viral load response during the treatment with" exact="Cidofovir" post="and Brincidofovir. Figure 2 Pharmacokinetics and drug composition of"/>
  <result pre="Cidofovir and Brincidofovir. Figure 2 Pharmacokinetics and drug composition of" exact="Cidofovir" post="and Brincidofovir. (a) The activated antiviral, cidofovir diphosphate, leads"/>
  <result pre="drug composition of Cidofovir and Brincidofovir. (a) The activated antiviral," exact="cidofovir" post="diphosphate, leads to chain termination as it is incorporated"/>
 </snippets>
</snippetsTree>
